Daniel O’Day, Gilead chairman and CEO (Photo by Jim Watson/AFP via Getty Images)

Gilead leads HIV grant­mak­ers list, tops Gates Foun­da­tion in a first for an­nu­al sur­vey

Gilead Sci­ences’ $100 mil­lion pledge to fight the HIV epi­dem­ic in the south­ern US states helped boost the bio­phar­ma to the top of an an­nu­al phil­an­thropic giv­ing list. The 19th an­nu­al study by Fun­ders Con­cerned About AIDS (FCAA) put Gilead at the top ahead of the Bill & Melin­da Gates Foun­da­tion for the first time since the study be­gan.

To­tal char­i­ta­ble giv­ing for 2020 was $707 mil­lion which, while just a 1% in­crease over the year be­fore, is still the high­est amount to date, said Sarah Hamil­ton, FCAA di­rec­tor of op­er­a­tions. FCAA tracks cash grants to ex­ter­nal or­ga­ni­za­tions for HIV re­search, treat­ment and oth­er pro­grams and does not in­clude big gov­ern­ment or pub­lic health fund­ing or in-kind con­tri­bu­tions from phar­ma com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.